CoChat

Disabling of receptor activator of nuclear factor-κB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.

Open access

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

The tumor necrosis factor family ligand, tumor necrosis factor-related activation-induced cytokine (TRANCE), and its receptors, receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG), are known to be regulators of development and activation of osteoclasts in bone remodeling. Sustained osteoclast activation that occurs through TRANCE-RANK causes osteopenic disorders such as osteoporosis and contributes to osteolytic metastases. Here, we report a rationally designed small molecule mimic of osteoprotegerin to inhibit osteoclast formation in vitro and limit bone loss in an animal model of osteoporosis. One of the mimetics, OP3-4, significantly inhibited osteoclast formation in vitro (IC(50) = 10 microm) and effectively inhibited total bone loss in ovariectomized mice at a dosage of 2 mg/kg/day. Unlike soluble OPG receptors, which preclude TRANCE binding to RANK, OP3-4 shows the ability to modulate RANK-TRANCE signaling pathways and alters the biological functions of the RANK-TRANCE receptor complex by facilitating a defective receptor complex. These features suggest that OPG-derived small molecules can be used as a probe to understand complex biological functions of RANK-TRANCE-OPG receptors and also can be used as a platform to develop more useful therapeutic agents for inflammation and bone disease.

Overview

Integrity signals

Registry

Crossref · 10.1074/jbc.m309690200

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 6

  1. Michigami, 2001, Cancer Res., 61, 1637
  2. Wang, 2002, Eur. J. Immunol., 32, 1090, 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P · DOI · Paper page
  3. Naismith, 1995, J. Inflamm., 47, 1
  4. Choi, 2001, Eur. J. Immunol., 31, 2179, 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X · DOI
  5. Holen, 2002, Cancer Res., 62, 1619
  6. Eghbali-Fatourechi, 2003, J. Clin. Invest., 111, 1221, 10.1172/JCI200317215 · doi:10.1172/jci200317215 · Paper page

Cited by

See all 95

Metadata

Authors
Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R.
Affiliations
  • University of Pennsylvania (US)
  • Abramson Cancer Center (US)
Corresponding author
Murali, Ramachandran
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2004-02
Volume
279
Issue
9
Pages
8269-8277
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2073112480
Cited by
92
References
74
Citations by year
2024: 2 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 3
FWCI
4.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
RANK, osteoprotegerin, trance, osteoclastogenesis, bone loss, osteoporosis, peptidomimetics, ovariectomized mice, bone remodeling, osteolytic bone metastasis
MeSH terms
Amino Acid Sequence, Animals, Binding Sites, Bone Resorption, Carrier Proteins, Disease Models, Animal, Female, Glycoproteins, Kinetics, Membrane Glycoproteins, Mice, Inbred C57BL, Models, Molecular, Oligopeptides, Osteoclasts, Osteoporosis, Ovariectomy, Peptide Fragments, Signal Transduction, NF-kappa B, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Mice, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.